NHS: Drugs
(asked on 11th April 2019) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what his Department’s (a) anticipated growth rate, (b) allowed growth rate and (c) anticipated rebate payment percentages will be for the current (i) Voluntary Scheme for Branded Medicines Pricing and Access and (ii) statutory scheme to control costs of branded health service medicines in each year of the operation of both schemes.
The following table shows the initial growth forecast for the Voluntary Scheme for Branded Medicines Pricing and Access and Statutory Scheme to control costs of branded health service medicines in each year of the operation of both schemes.
Voluntary Scheme | 2019 | 2020 | 2021 | 2022 | 2023 |
Initial forecast growth rate of Voluntary Scheme Measured Sales | 5.91% | 7.16% | 8.90% | 9.53% | 9.12% |
Voluntary Scheme Allowed Growth Rate | 2.0% | 2.0% | 2.0% | 2.0% | 2.0% |
Initial payment percentage for Voluntary Scheme members | 9.6% |
|
|
|
|
Estimated 2020 future payment percentage for Voluntary Scheme members |
| 14.2% |
|
|
|
Statutory Scheme | 2019 | 2020 | 2021 | 2022 | 2023 |
Initial forecast growth rate of Statutory Scheme Measured Sales | 5.8% | 7.0% | 8.7% |
|
|
Statutory Scheme payment % | 9.9% | 14.7% | 20.5% |
|
|
Statutory Scheme allowed growth rate:
“The payment percentages are calculated to limit the growth rate of branded health service medicines sales consistent with the average annual growth rate agreed in the 2014 voluntary scheme, which was an average of 1.1% per annum growth.”
These figures are published in the following publications:
Page 13 of the 2019 Voluntary Scheme Annex 3 which is available at the following link:
Page 8 of the Statutory Scheme Impact Assessment which is available at the following link: